CognitrexCancerDigest

Eisai Co., Ltd. announced today that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research. In this joint research and development, Eisai and PGDx will create a kitted cancer gene panel test that enables a comprehensive analysis of mutation in more than 500 cancer gene using liquid biopsy with blood samples. Additionally, the kit will be used in our drug discovery and development. In Eisai's medium-term business plan "EWAY2025", Eisai is pursuing creating innovation focused in neurology area and oncology area aimed at realizing "prediction / prevention" and "cure". Aiming to acquire next-generation sequencing technology for realizing personalized cancer medicine, Eisai has concluded a joint research and development agreement with PGDx, a US bio-venture with liquid biopsy genomic expertise. By analyzing the circulating tumor D

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for Darzalex® (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). This approval is based on results from Part one of the Phase 3 CASSIOPEIA ( MMY3006 ) study, published in The Lancet[5] in June 2019 and presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting. “The effectiveness of first-line treatment is critical to maximise time until relapse. So, we asked ourselves, can we improve the standard of care that is bortezomib, thalidomide and dexamethasone (VTd) to provide patients with valuable extra time?” said Philippe Moreau, M.D., principal investigator and Head of the Haematology Department at the University Hospital of Nantes, France. “The CASSIOPEIA study an

Hyderabad: Taiho Pharmaceutical , a Japanese pharmaceuticals company and its group company have moved a US court against Natco Pharma , alleging that the Indian drug maker was attempting to come out with a generic version of its cancer medicine ' Lonsurf ,' before expiration of its patent. In a petition filed in the United States District Court for the District Court of Delawareon December 30, Taiho alleged that the Indian drug maker's proposed generic Lonsurf (trifluridine and tipiracil) will infringe the patent and sought the court to pass an injunction order against manufacturing, importing and selling that drug in the US. Taiho Oncology , Inc. sells and distributes Lonsurf in the United States, while Taiho Pharmaceuticalis the owner of all the right, title, and interest of the patent. The Japanese company sought the court to pass an injunction order enjoining Natco from attempting to manufacture or sell Lonsurf in the US. Earlier in November, 2019, through a letter to